AstraZeneca Pharma India Ltd.
Description AstraZeneca Pharma India Limited engages in the discovery, development, and marketing of pharmaceutical products in India and internationally. The company primarily provides products in the areas of cardiovascular, gastrointestinal, infection, neuroscience, oncology, respiratory, inflammation, and maternal healthcare. Its products include Onglyza, Betaloc, Betaloc H, Seloken XL, Imdur, Ramace, Ramace H, Plendil, Zestril, Crestor, Seloram, Vigocil, Vigocil M, Nitract SR, Valfect, Valfect H, Olways, Olways H, and Olways AM for cardiovascular diseases; Mits Linctus Codeinae Co, Mits Linctus DX, Bricarex, Bricarex A, Bricacef, Bricacef PED, Bricanyl, Symbicort, Rhinofex, Rhinomax, and Rhinocort for respiratory diseases; and Prostodin, Cerviprime, Primiprost, Partocin, Gladis, and Valenzia for maternal healthcare. The company also provides Arimidex, Nolvadex, Iressa, Zoladex, Casodex, and Faslodex for oncology; Meronem, Vancocin CP, Actamase, Enclere, Remergin, and Rescade for infection; Xylocaine, Sensorcaine, Diprivan, and Naropin for neuroscience; and Neksium for gastrointestinal problems. The company is headquartered in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. To view the detailed information, you need to SUBSCRIBE with us. |
 |